On February 10, 2020, Arbutus Biopharma Corporation (the “Company”) issued a press release announcing its decision to discontinue AB-452 and pursue development of a next generation HBV specific oral RNA-destabilizer. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference herein.

Also on February 10, 2020, the Company posted an updated corporate presentation on its website at www.arbutusbio.com. A copy of the presentation is filed herewith as Exhibit 99.2 and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Arbutus Biopharma Corp Exhibit
EX-99.1 2 a20200210ab452pressrelea.htm EXHIBIT 99.1 a20200210ab452pressrelea Arbutus Announces Decision to Discontinue AB-452 and to Pursue Development of a Next Generation HBV Specific Oral RNA-Destabilizer Arbutus expects to announce AB-729 Preliminary Phase 1a/1b Data late Q12020 WARMINSTER,…
To view the full exhibit click here

About Arbutus Biopharma Corporation (NASDAQ:ABUS)

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV). It is developing a pipeline focused on advancing Ribo Nucleic Acid interference therapeutics (RNAi) using its Lipid Nanoparticle technology. The Company’s lead RNAi HBV candidate, ARB-1467, eliminates HBV surface antigen expression in patients chronically infected with HBV. ARB-1467 is being developed as a multi-component RNAi therapeutic that targets various sites on the HBV genome. It is also developing small molecule covalently closed circular deoxyribonucleic acid (cccDNA) formation inhibitors, multiple small molecule orally bioavailable inhibitors of HBV surface antigen production and secretion, cccDNA epigenetic modifiers and stimulator of interferon genes agonists.